Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has issued an update.
Shanghai Henlius Biotech has obtained Australian approval to begin a phase 1 clinical trial for HLX48, a bispecific antibody-drug conjugate targeting EGFR and c-MET for advanced or metastatic solid tumors. The therapy is designed to combine targeted cytotoxic payload delivery with immune-mediated mechanisms to inhibit tumor growth while aiming for a favorable safety profile.
Preclinical data suggest HLX48 offers promising anti-tumor efficacy, and it would be the first bispecific ADC against both EGFR and c-MET if successfully commercialized globally. The company, however, cautions investors that successful development and commercialization are not guaranteed, underscoring both the opportunity and clinical risk inherent in this early-stage asset.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$99.78 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a China-based biopharmaceutical company specializing in the independent development of innovative biologic drugs, including antibody-based therapies. Listed in Hong Kong, the company focuses on oncology and other serious diseases, targeting global markets through both in-house R&D and international clinical development.
Average Trading Volume: 934,733
Technical Sentiment Signal: Buy
Current Market Cap: HK$39.13B
See more insights into 2696 stock on TipRanks’ Stock Analysis page.